Eton Pharmaceuticals Q3 revenue jumps 158% on portfolio sales growth; raises 2026 outlook

Overview

• U.S. rare disease drugmaker's Q3 revenue rose 158% yr/yr to record $57.9 mln

• Adjusted EPS for Q3 was $0.50, with adjusted EBITDA margin at 49%

• Company raised 2026 revenue and adjusted EBITDA margin guidance

Outlook

• Eton raises 2026 revenue guidance to more than $175 mln, up from over $145 mln

• Company lifts 2026 adjusted EBITDA margin outlook to at least 40%, up from 35%

• Eton expects full-year 2026 adjusted gross margin to exceed 70%

Result Drivers

• PORTFOLIO SALES GROWTH - Revenue growth driven by addition of HEMANGEOL sales and higher sales of INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, DESMODA and Carglumic Acid

• PATIENT GROWTH - Record active patient counts across key products contributed to sales growth

• PRODUCT MIX - Favorable change in product mix contributed to higher gross profit

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $70.00, about 38% above its November 4 closing price of $50.72

• The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 33 three months ago

Reuters Recommended Reads

• Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

• Nov 3 - Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales

• Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)